Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Predictmedix ( (TSE:PMED) ) has shared an update.
Predictmedix AI Inc. announced the successful closing of the first tranche of its non-brokered private placement, raising $460,150 through the issuance of 9,203,000 units. This financing round, which includes significant insider participation, underscores strong internal confidence in the company’s growth and innovation. The funds raised are part of Predictmedix’s strategic efforts to expand its shareholder base and engage with global investors, following its participation in major European investment conferences and roadshows.
Spark’s Take on TSE:PMED Stock
According to Spark, TipRanks’ AI Analyst, TSE:PMED is a Underperform.
The overall stock score for Predictmedix is driven by its significant financial challenges, including negative revenue and profitability, and a weak balance sheet. While technical indicators show short-term positive momentum, the company’s poor financial health and unattractive valuation metrics weigh heavily on its score.
To see Spark’s full report on TSE:PMED stock, click here.
More about Predictmedix
Predictmedix AI Inc. is an emerging provider of rapid health screening and remote patient care solutions globally. The company utilizes proprietary artificial intelligence technology in its Smarthealth AI stations, which use multispectral cameras to analyze physiological data patterns and predict various health issues. Their platform empowers medical professionals with AI-powered tools to improve patient health outcomes.
YTD Price Performance: 250.0%
Average Trading Volume: 203,439
Technical Sentiment Signal: Buy
Current Market Cap: C$6.74M
See more data about PMED stock on TipRanks’ Stock Analysis page.